Lacosabil (Lacosamide)

Lacosamide is an antiepileptic that modulates neuronal sodium channels to control seizure activity.

• Partial‑onset seizures: reduces seizure frequency as adjunctive therapy.
• Adjunctive therapy for epilepsy: improves overall seizure control when added to existing regimens.
• Focal seizures with secondary generalization: helps prevent spread of seizure activity.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyperexcitable neuronal membranes. It also binds to the collapsin response mediator protein‑2 (CRMP‑2), influencing neuronal differentiation and axonal outgrowth, thereby contributing to its antiepileptic effect.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Nausea: mild gastrointestinal upset.
• Fatigue: increased tiredness or lack of energy.
• Headache: mild to moderate cranial pain.
• Diplopia: occasional double vision.
• Somnolence: feeling unusually sleepy.

Serious or Rare Side Effects

• Cardiac arrhythmia: PR‑interval prolongation that may affect heart rhythm.
• Atrioventricular block: impaired conduction between atria and ventricles.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal ideation: emergence of thoughts of self‑harm.
• Hepatic enzyme elevation: significant increase in liver function tests.
• Respiratory depression: rare but potentially life‑threatening breathing difficulty.

When prescribing Lacosabil, clinicians should consider several safety aspects.

• Renal impairment: dose adjustment may be required and renal function should be monitored.
• Hepatic impairment: monitor liver enzymes regularly, especially in patients with pre‑existing liver disease.
• Cardiac conduction: obtain baseline ECG and monitor for PR‑interval changes.
• Pregnancy: risk category unknown; discuss potential benefits and risks with the patient.
• Concomitant CNS depressants: may increase sedation and should be used with caution.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosabil can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital): may markedly reduce lacosamide plasma levels.
• Drugs that prolong PR interval (e.g., verapamil, diltiazem): may increase risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely)

• Alcohol: can enhance central nervous system depression.
• Other antiepileptics: may have additive effects on seizure control and side‑effect profile.
• Antidepressants (e.g., SSRIs): monitor for increased dizziness or somnolence.